SCHEMBL21022891

SCHEMBL21022891

CCNC(=O)[C@@]12CCC3C(C(=O)C=C4[C@@]5(C)C=C(C#N)C(=O)[C@@](C)(O)C5CC[C@]43C)C1CC(C)(C)CC2

nearest known ligand 0.63

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ MBOAT4 Q96T53 4/20 0.63
▸ RORC P51449 1/20 0.56
▸ NOS2 P35228 8/20 0.48
▸ NFE2L2 Q16236 3/20 0.48
▸ KEAP1 Q14145 2/20 0.48
▸ USP7 Q93009 2/20 0.48
▸ CYP3A4 P08684 2/20 0.48
▸ CYP2C19 P33261 2/20 0.48
▸ USP2 O75604 1/20 0.48
▸ STAT3 P40763 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ CCR6 P51684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21022618 0.93 MBOAT4 (0.73) MBOAT4RORCNOS2NFE2L2KEAP1
SCHEMBL22293723 0.93 MBOAT4 (0.73) MBOAT4RORCNOS2NFE2L2KEAP1
SCHEMBL20750767 0.93 MBOAT4 (0.73) MBOAT4RORCNOS2NFE2L2KEAP1
SCHEMBL23544236 0.93 MBOAT4 (0.73) MBOAT4RORCNOS2NFE2L2KEAP1
SCHEMBL22428591 0.93 MBOAT4 (0.73) MBOAT4RORCNOS2NFE2L2KEAP1
SCHEMBL21022598 0.91 MBOAT4 (0.65) MBOAT4RORCNOS2NFE2L2KEAP1
SCHEMBL21022355 0.91 MBOAT4 (0.61) MBOAT4RORCNOS2NFE2L2KEAP1
SCHEMBL21022539 0.88 RORC (0.72) MBOAT4RORCNOS2NFE2L2KEAP1
SCHEMBL21022889 0.88 RORC (0.72) MBOAT4RORCNOS2NFE2L2KEAP1
SCHEMBL21085475 0.86 MBOAT4 (0.55) MBOAT4RORCNOS2NFE2L2KEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250130-A1 C4-MODIFIED OLEANOLIC ACID DERIVATIVES FOR INHIBITION OF IL-17 AND OTHER USES REATA PHARMACEUTICALS, INC. 2023-08-10 — — US disclosed
US-11584775-B2 C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses REATA PHARMACEUTICALS, INC. (US) 2023-02-21 — — US disclosed
US-20190153022-A1 C4-MODIFIED OLEANOLIC ACID DERIVATIVES FOR INHIBITION OF IL-17 AND OTHER USES REATA PHARMACEUTICALS, INC. 2019-05-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190153022-A1 C4-MODIFIED OLEANOLIC ACID DERIVATIVES FOR INHIBITION OF IL-17 AND OTHER USES IL17A, IL23R, ALOX15 MBOAT4 1187/4885RORC 62/4885NOS2 785/4885
US-20230250130-A1 C4-MODIFIED OLEANOLIC ACID DERIVATIVES FOR INHIBITION OF IL-17 AND OTHER USES IL17A, IL23R, ALOX15 MBOAT4 954/4885RORC 44/4885NOS2 622/4885
US-11584775-B2 C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses IL17A, IL23R, ALOX15 MBOAT4 1187/4885RORC 62/4885NOS2 785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback